SPECIAL REPORT
Several studies presented at the ACTRIMS Forum 2022 provided some additional details on the COVID-19 vaccine response among MS patients treated with anti-CD20 therapies. The data suggest that vaccine response may differ somewhat among anti-CD20 agents, which may be related to the depth and/or duration of B cell suppression, the timing of vaccination and patient factors such as age. Read More
COVID-19 infections are generally uncommon in healthcare workers and MS patients who have been previously infected or who are fully vaccinated. However, it should be noted that most studies were done prior to the emergence of the Omicron variant. Read More
Click here to watch Dr. Virender Bhan discuss the case and the responses to the survey.
Elizabeth, 28, is referred by her family practitioner with a note that her MRI report is suggestive of MS. She is married with two children and is currently employed as a middle school teacher. She has a history of episodic migraine but is otherwise healthy. She reports no neurological symptoms. There is no history of recreational drug use. There is no family history of demyelinating diseases including MS. Elizabeth tells you she has a maternal aunt with fibromyalgia. Read More
Part 2
The onset of secondary-progressive multiple sclerosis (SPMS) may be seen as the time at which progressive disability accumulation becomes clinically evident. The process of irreversible disability likely begins much earlier during the relapsing phase; however, a diagnosis is typically made only after relapses have ceased or a level of disability has been reached, which results in a considerable diagnostic delay (Katz Sand et al. Mult Scler 2014;20:1654-1657) (see also Part 1 of this article). Read More